|
REMS Provision Left Out of PDUFA, GPhA Criticizes Lack of House Access
Generic-drug makers are raising concerns with their access to House user fee bill discussions because unlike the Senate, House lawmakers didn’t hold a joint meeting with the FDA, PhRMA and GPhA on certain cost-saving provisions of its FDA user fee bill.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives